根據 位華爾街分析師的預測,Virax Biolabs Group Ltd 的收入預期範圍從 $ 到 $
Virax Biolabs Group Ltd 的盈利品質評分是多少?
Virax Biolabs Group Ltd 的盈利品質評分為 B/32.784084。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Virax Biolabs Group Ltd 何時發布財報?
Virax Biolabs Group Ltd 的下一份財報預計在 發布
Virax Biolabs Group Ltd 的預期收益是多少?
根據華爾街分析師的預測,Virax Biolabs Group Ltd 的預期收益為 $
Virax Biolabs Group Ltd 是否超出收益預期?
Virax Biolabs Group Ltd 最近的收益為 $, 預期。
關鍵數據
前收市價
$2.81
開盤價
$2.78
當日範圍
$2.76 - $2.82
52週區間
$2.5 - $27.5
交易量
21.4K
平均成交量
1.8M
股息收益率
--
每股盈餘 (TTM)
-1.25
市值
$55.1M
什麼是 VRAX?
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).